Showing results (11-20 of 43) with videos related to

Sort By:
Pageof 5
Nihon Shokakibyo Gakkai Zasshi = the Japanese Journal of Gastro-Enterology|November 13, 2018
[Pulmonary tuberculosis following anti-tumor necrosis factor-α therapy in Crohn's disease:a case report]Yusuke Hara, Taku Kobayashi, Shinji Okabayashi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 18, 2012
Compound EGFR mutations and response to EGFR tyrosine kinase inhibitorsSusumu Kobayashi, Hannah M Canepa, Alexandra S Bailey, et al.
Lung Cancer (Amsterdam, Netherlands)|July 9, 2014
Claudin-1 is a novel target of miR-375 in non-small-cell lung cancerSatoshi Yoda, Kenzo Soejima, Junko Hamamoto, et al.
Lung Cancer (Amsterdam, Netherlands)|November 9, 2013
Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancerNorihiro Yamaguchi, Antonio R Lucena-Araujo, Sohei Nakayama, et al.
Plos One|March 14, 2015
CCAAT/enhancer binding protein β is dispensable for development of lung adenocarcinomaYi Cai, Ayako Hirata, Sohei Nakayama, et al.
Cancer Chemotherapy and Pharmacology|September 8, 2019
A phase II trial of induction of erlotinib followed by cytotoxic chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer patientsTetsuo Tani, Katsuhiko Naoki, Hiroyuki Yasuda, et al.
Cancer Chemotherapy and Pharmacology|December 15, 2010
A phase I study of S-1 and irinotecan combination therapy in previously treated advanced non-small cell lung cancer patientsSatoshi Yoda, Kenzo Soejima, Hiroyuki Yasuda, et al.
Molecular Medicine Reports|June 14, 2013
Identification of microRNAs differentially expressed between lung squamous cell carcinoma and lung adenocarcinomaJunko Hamamoto, Kenzo Soejima, Satoshi Yoda, et al.
Pageof 5